Clinical trials: Empagliflozin
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin…
- Trial name
- NCT07213895
- Testing
- Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Heart Failure, Diabetes Mellitus
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
The investigators hypothesise that empagliflozin 10mg daily will have haemodynamic, cardiac, and renal benefits compared to placebo over 36 weeks in heart failure patients with type 2 diabetes (or pre-diabetes), leading to…
- Trial name
- SUGAR-DM-HF (NCT03485092)
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- NHS Greater Glasgow and Clyde
Type 2 Diabetes Mellitus
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and…
- Trial name
- NCT06483243
- Testing
- Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease, Glycogen Metabolism
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Background: Severe congenital neutropenia (SCN) is an immune system disease. People with SCN do not have enough of a kind of white blood cell called neutrophils. This means they get sick easily from infections.
- Conditions
- Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
- Trial name
- NCT05078879
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses.
- Trial name
- NCT02172196
- Testing
- BI 10773, Sitagliptin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- EGITO (NCT04970108)
- Testing
- Egito, Empagliflozin + telmisartan
- Sponsor
- EMS
PreDiabetes, Prediabetic State
Use of Empagliflozin to Treat Prediabetes
The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes.
- Conditions
- PreDiabetes, Prediabetic State, Overweight and Obesity
- Trial name
- NCT05426525
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oregon State University
Kidney Disease, Chronic
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.
- Trial name
- NCT06531824
- Testing
- BI 690517, Empagliflozin
- Where
- 562 sites in United States, Argentina and 18 more
- Volunteers
- 8,371 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of…
- Trial name
- NCT01370005
- Testing
- BI 10773
- Where
- 120 sites in United States, Canada and 10 more
- Volunteers
- 825 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
People with newly diagnosed type 2 diabetes treated with metformin that have not reached their HbA1c target (42-64 mmol/mol) will be recruited to the study.
- Trial name
- DiaSpax (NCT05501483)
- Testing
- Pioglitazone 45 mg, Empagliflozin 25 MG, Semaglutide 7 MG
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Karolinska Institutet
STEMI, No-Reflow Phenomenon
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. A significant contributor to this issue is reperfusion injury, which enlarges the infarction…
- Trial name
- EMPA-PCI (NCT06342141)
- Testing
- Empagliflozin 25 milgrams (Mg), Empagliflozin 10 Mg
- Where
- Mexico
- Volunteers
- 162 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Type 2 Diabetes
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
This study is a multicenter, randomized, controlled study. A sample size of 240 cases is proposed to be included. The inclusion criteria are: (1) patients with newly diagnosed type 2 diabetes; (2) age between 18 and 65 years old…
- Trial name
- TRED (NCT07374328)
- Testing
- Semaglutide (1 Mg Dose), Sitagliptin (DPP4 inhibitor)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Lupus Nephritis
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.
- Trial name
- NCT06113900
- Testing
- Dapagliflozin 10mg Tab orally once daily
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Kidney Transplant, Chronic Kidney Disease
Empagliflozin Treatment in Kidney Transplant Recipients
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.
- Trial name
- SEKTR (NCT06013865)
- Testing
- Empagliflozin
- Where
- 5 sites in United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development
Perioperative Complication
SGLT2 Inhibitors and Perioperative Period
The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.
- Trial name
- NCT06326528
- Testing
- SGLT2 inhibitor
- Volunteers
- 100 people
- Sponsor
- Assiut University
Pharmacogenomic, Pharmacokinetics
Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin
The aim of this works is to investigate the effect of genetic polymorphism of snps on human response to treatment with empagliflozin and its correlation with with pharmacokinetic parameters in Egyptian subjects
- Trial name
- NCT05036421
- Testing
- Empagliflozin 10 milligram
- Where
- Egypt
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Type 2 Diabetes Mellitus
A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017
This study aims to describe the prevalence of type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) according to the (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus…
- Trial name
- NCT04927858
- Testing
- Empagliflozin
- Where
- Sweden
- Volunteers
- 460,558 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated…
- Trial name
- RACELINES (NCT03433248)
- Testing
- EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22)
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- M.H.H. Kramer
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer